as of 08-13-2026 3:46pm EST
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.1B | IPO Year: | 2026 |
| Target Price: | N/A | AVG Volume (30 days): | 661.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $17.22 - $20.50 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
10% Owner
Avg Cost/Share
$18.00
Shares
140,000
Total Value
$2,520,000.00
Owned After
2,008,024
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$18.00
Shares
140,000
Total Value
$2,520,000.00
Owned After
2,008,024
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Foresite Capital Management V, LLC | LTGO | 10% Owner | Aug 10, 2026 | Buy | $18.00 | 140,000 | $2,520,000.00 | 2,008,024 | |
| Tananbaum James B. | LTGO | Director, 10% Owner | Aug 10, 2026 | Buy | $18.00 | 140,000 | $2,520,000.00 | 2,008,024 |
See how LTGO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LTGO Latigo Biotherapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.